Kalbe Farma Tbk PT operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Kalbe Farma Tbk PT with three other
pharmaceutical manufacturers in Asia:
Huapont-Nutrichem Co Ltd
sales of 9.11 billion Chinese Renmimbi [US$1.32 billion]
of which 72%
was Agricultural Business),
Chongqing Taiji Industry (Group)
(8.73 billion Chinese Renmimbi [US$1.26 billion]
of which 68%
was Trading), and
Cadila Healthcare Ltd
based in India
(94.30 billion Indian Rupees [US$1.27 billion]
of which 100%
was Pharmaceutical Products).
Kalbe Farma Tbk PT reported sales of 20.18 trillion Indonesian Rupiahs (US$1.33 billion)
December of 2017.
increase of 4.2%
versus 2016, when the company's sales were 19.37 trillion Indonesian Rupiahs.
Sales at Kalbe Farma Tbk PT have increased during each of the previous five years
(and since 2012, sales have increased a total of 48%).
Sales of Nutritionals saw an increase
that was more than double the company's growth rate: sales were up
8.7% in 2017, from
5.61 trillion Indonesian Rupiahs to 6.10 trillion Indonesian Rupiahs.